Ginkgo Bioworks Holdings, Inc. (DNA)

Market Cap	535.07M
Revenue (ttm)	217.95M
Net Income (ttm)	-651.19M
Shares Out	53.08M
EPS (ttm)	-12.86
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,568,396
Open	8.46
Previous Close	8.74
Day's Range	8.40 - 10.53
52-Week Range	5.26 - 74.00
Beta	1.17
Analysts	Hold
Price Target	37.80 (+275.0%)
Earnings Date	Nov 12, 2024

About DNA

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 1,218
• Stock Exchange: NYSE
• Ticker Symbol: DNA
• Website: https://www.ginkgobioworks.com

Financial Performance

In 2023, Ginkgo Bioworks Holdings's revenue was $251.46 million, a decrease of -47.36% compared to the previous year's $477.71 million. Losses were -$892.87 million, -57.58% less than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for DNA stock is "Hold." The 12-month stock price forecast is $37.8, which is an increase of 275.00% from the latest price.

Price Target

$37.8

(275.00% upside)

Analyst Consensus: Hold